"Rhythm’s stock climbs on encouraging Phase II obesity drug data" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Rhythm Pharmaceuticals' potential first-in-class HO drug, strong pipeline, and limited competition offer blockbuster potential. Click to read why RYTM is a Buy.

Rhythm PharmaceuticalsRYTM shares surged to a record high Wednesday on promising results for a drug that could treat a rare ...

The young golfer understood that the wind was a serious obstacle, so he knew that patience could be a decisive factor.

Rhythm Pharmaceuticals’ push to move obesity patients from jabs to tabs has stayed on beat. | Rhythm Pharmaceuticals’ push to ...

The next program of the Rhythm on the River Arts Series in Grand Rapids will be presented by Lake Effect Clarinet Quartet on ...

Rory McIlroy stressed after the end of the first round that everything seemed a bit chaotic at the beginning, but as the day ...

Dum is a mesmerizing auditory journey crafted by rhythm maestros Bickram Ghosh and Taufiq Qureshi. This avant-garde piece ...

Melbourne-via-Canberra post-punk five-piece Mr. Industry break down each song on their debut EP, exclusively for 'Music Feeds ...

Preparing for Pride and remembering Consuelo Faust the "the rehearsals have been so loving and joyous and full of intention.” ...

Also known as Double Trouble, Tommy Shannon and Chris Layton laid down an unfaltering groove for SRV’s 1983 debut ...

Rhythm said results of the recent trial were also consistent with BMI reductions achieved with setmelanotide therapy in similar patient populations in past trials. Setmelanotide, an existing ...